glp-1 news today october 23 2025 President Trump announced that Medicare will cover semaglutide (Wegovy) and tirzepatide (Zepbound) for weight management indications for people with obesity. Our senior staff writer Kristen Monaco breaks it down on the latest GLP-1 Agonists Market Report 2025-2033,

Adds a nice kick

Kizawa Y, Sekikawa T, Kageyama M, Tomobe H, Kobashi R, Yamada T (2021) Effects of anthocyanin, astaxanthin, and lutein on eye functions: a randomized, double-blind, placebo-controlled study

Some patients choose to discuss peptide therapy alongside medical weight loss, hormone optimization, or other wellness-focused programs

And then the third piece that I hope is has been made clear, but I just want to double click on it is if you are making a decision in any capacity to wean, which I prefer weaning period, or to come off of the medication, you have to go through a whole process of restarting your own and then we have to be checking it

Those with Neurological Symptoms: B12 deficiency can cause nerve damage, leading to symptoms like numbness, tingling, balance issues, or memory problems